3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Prostatic Neoplasms
3
Glioblastoma
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Neurodegenerative Diseases
1
Malignant Solid Neoplasm
1
Kidney Neoplasms
1
Ischemic Stroke
1
Hypoxia
1
Hemorrhagic Stroke
1
Head and Neck Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Childhood Brain Neoplasm
1
Central Nervous System Vascular Malformations
1
Central Nervous System Infections
1
Carcinoma, Medullary
1
Cancer of Lymph Node
1
Interventions
Cyclophosphamide
10
Irinotecan
8
Melphalan
7
Vincristine
6
Temozolomide
6
Doxorubicin
6
Busulfan
6
Topotecan
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
Ifosfamide
4
Filgrastim
4
Etoposide
4
Albumin-Bound Paclitaxel
4
Trabectedin
3
Sirolimus
3
Nivolumab
3
130-nm albumin-bound paclitaxel
3
pegfilgrastim
2
olaparib
2
fludarabine phosphate
2
fludarabine
2
eribulin
2
cixutumumab
2
abemaciclib
2
X-Rays
2
Radiotherapy, Intensity-Modulated
2
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Sarcoma, Ewing
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts